Fagan Associates’s Gilead Sciences GILD Stock Holding History

Fagan Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$214K	Buy	+1,532	New	+$215K	0.03%	130
2023 Q4	–	Sell	-6,515	Closed	-$488K	–	114
2023 Q3	$488K	Buy	6,515 +770	+13%	+$59.2K	0.12%	82
2023 Q2	$443K	Buy	5,745 +600	+12%	+$47.9K	0.11%	85
2023 Q1	$427K	Buy	5,145 +1,679	+48%	+$139K	0.11%	92
2022 Q4	$298K	Buy	+3,466	New	+$274K	0.08%	104
2018 Q1	–	Sell	-34,594	Closed	-$2.48K	–	105
2017 Q4	$2.48K	Buy	34,594 +155	+0.5%	+$11.8K	1%	30
2017 Q3	$2.79M	Buy	34,439 +1,364	+4%	+$104K	1.38%	26
2017 Q2	$2.34M	Buy	33,075 +845	+3%	+$56.2K	1.22%	30
2017 Q1	$2.19M	Sell	32,230 -870	-3%	-$61.2K	1.21%	28
2016 Q4	$2.37M	Buy	33,100 +320	+1%	+$23.8K	1.37%	26
2016 Q3	$2.59M	Sell	32,780 -5,385	-14%	-$437K	1.59%	23
2016 Q2	$3.18M	Buy	+38,165	New	+$3.39M	2.05%	16
2015 Q3	–	Sell	-62,655	Closed	-$7.34M	–	92
2015 Q2	$7.34M	Buy	+62,655	New	+$6.85M	4.89%	2
2014 Q2	–	Sell	-64,835	Closed	-$4.59M	–	89
2014 Q1	$4.59M	Buy	+64,835	New	+$5.08M	3.98%	4

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fagan Associates's GILD Position: Q1 2026 in Review

Fagan Associates opened a new position in Gilead Sciences (GILD) in Q1 2026: 1,532 shares worth $214K. The stake represents 0.03% of the portfolio and ranks #130 among its holdings. This is a return to the name: Fagan Associates previously reported a position in GILD as recently as Q3 2023.

Fagan Associates first reported a position in GILD in Q1 2014 and has held it in 14 quarters since. The position peaked at $7.34M in Q2 2015. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Fagan Associates held 1,532 shares of Gilead Sciences worth $214K as of Q1 2026.
Gilead Sciences was a new Fagan Associates position in Q1 2026.
Gilead Sciences made up 0.03% of Fagan Associates's portfolio in Q1 2026, its #130 holding.
Fagan Associates first reported a position in Gilead Sciences in Q1 2014 and has held it in 14 quarters since.
Fagan Associates's Gilead Sciences position peaked at $7.34M in Q2 2015.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Fagan Associates's 13F filing for Q1 2026, filed 4 May 2026.